Breaking News, Collaborations & Alliances

Karo Bio, Pfizer Expand RORgamma Research Pact

To discover and develop modulators for the treatment of autoimmune diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Karo Bio and Pfizer have extended their existing collaboration to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases through 2014. Pfizer will continue to provide full funding for research costs. Karo Bio is eligible to receive more than $200 million in milestone payments in addition to royalties.  “We are pleased that Pfizer has chosen to extend our partnership. The decision illustrates the potential of the science behind RORgamma and its ap...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters